Q32 Bio (QTTB)

• Market cap: $37.5M
• 1 day: 3.04%
• 5 days: -10.56%
• 1 month: 33.19%
• 3 months: 68.51%
• 6 months: 81.55%
• Year to date: -11.59%
• 1 year: -12.86%
• 5 years: -98.49%
• 10 years: -99.09%
• Sector: Healthcare
• Industry: Biotechnology

About: Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.

Employees: 26